Financial Performance - The company's revenue for Q1 2023 was CNY 373,166,292.20, representing a 1.42% increase compared to CNY 367,925,505.63 in the same period last year[13] - Net profit attributable to shareholders decreased by 14.43% to CNY 138,433,086.41 from CNY 161,777,968.14 year-on-year[13] - The total comprehensive income for the first quarter of 2023 was approximately CNY 138.43 million, a decrease from CNY 161.78 million in the same period last year, representing a decline of about 14.4%[43] - Basic and diluted earnings per share for the first quarter were CNY 0.32, down from CNY 0.37 in the previous year, indicating a decrease of approximately 13.5%[43] Cash Flow - The net cash flow from operating activities increased by 29.21% to CNY 28,782,865.71 compared to CNY 22,275,788.10 in the previous year[13] - Cash inflow from operating activities totaled CNY 446.38 million, an increase of 24.8% compared to CNY 357.66 million in the same period last year[43] - Cash outflow from operating activities was CNY 417.60 million, up from CNY 335.38 million, resulting in a net cash flow from operating activities of CNY 28.78 million, an increase of 29.5% year-over-year[43] - The company's cash flow statement indicates a stable cash position, with no significant changes reported in cash flow from operating activities[26] - The ending balance of cash and cash equivalents was CNY 530.38 million, compared to CNY 470.60 million at the end of the previous year, reflecting a decrease in cash reserves[45] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 6,199,028,028.60, a 25.50% increase from CNY 4,939,389,761.87 at the end of the previous year[13] - The company's cash and cash equivalents decreased to CNY 558,387,952.23 from CNY 777,248,693.86[19] - Accounts receivable increased to CNY 1,014,589,461.88 from CNY 924,070,859.41, indicating a growth of approximately 9.7%[19] - Current liabilities decreased to CNY 1,248,308,071.79 from CNY 1,484,098,044.10, a reduction of approximately 15.9%[22] - Long-term borrowings increased to CNY 999,238,137.82 from CNY 689,214,991.96, representing a growth of about 45%[22] - The total liabilities rose to ¥3,258,533,476.71 from ¥3,156,510,196.83, an increase of approximately 3.23%[36] Investment and Expenses - The company reported a significant increase in investment income, rising by 1646.10% to CNY 2,463,766.47 from CNY 141,101.23 in the previous year[16] - Research and development expenses amounted to ¥61,517,923.07, compared to ¥56,659,055.19 in the previous period, indicating an increase of about 8.25%[24] - Total operating costs increased to ¥243,515,781.30 from ¥212,061,775.12, marking a rise of about 14.85%[24] - Tax expenses decreased to ¥1,076,155.70 from ¥6,010,278.61, a reduction of approximately 82.06%[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,586[16] - The company has a total of 113,674,906 shares, with 25% of these shares subject to a lock-up period[18] - The total equity attributable to shareholders increased to ¥2,940,494,551.89 from ¥2,802,510,631.14, reflecting a growth of about 4.93%[36]

Financial Performance - The company's operating revenue for Q1 2023 was CNY 373,166,292.20, an increase of 1.42% compared to CNY 367,925,505.63 in the same period last year[5] - Net profit attributable to shareholders decreased by 14.43% to CNY 138,433,086.41 from CNY 161,777,968.14 year-on-year[5] - The net profit after deducting non-recurring gains and losses was CNY 128,887,445.84, down 13.28% from CNY 148,627,173.03 in the previous year[5] - Total operating revenue for the current period reached ¥373,166,292.20, an increase from ¥367,925,505.63 in the previous period, representing a growth of approximately 0.66%[32] - Net profit for the current period was ¥138,433,086.41, down from ¥161,777,968.14, indicating a decrease of approximately 14.39%[34] - The total comprehensive income attributable to the parent company's owners was approximately $138.43 million, down from $161.78 million in the previous period, representing a decrease of about 14.4%[49] - Basic and diluted earnings per share were both $0.32, compared to $0.37 in the previous period, reflecting a decline of approximately 13.5%[49] Cash Flow - The net cash flow from operating activities increased by 29.21% to CNY 28,782,865.71 compared to CNY 22,275,788.10 in the same period last year[5] - Cash inflow from operating activities totaled approximately $446.38 million, an increase of about 25% from $357.66 million in the previous period[49] - Cash outflow from operating activities was approximately $417.60 million, up from $335.38 million, indicating an increase of about 24.5%[49] - The net cash flow from operating activities was approximately $28.78 million, an increase of about 29.5% compared to $22.28 million in the previous period[49] - Cash outflow from investing activities was approximately $380.89 million, compared to $319.84 million in the previous period, representing an increase of about 19.1%[52] - The net cash flow from investing activities was negative at approximately $380.89 million, worsening from a negative $215.46 million in the previous period[52] - Cash inflow from financing activities was approximately $416.41 million, down from $448.28 million, indicating a decrease of about 7.1%[52] - The net cash flow from financing activities was approximately $137.24 million, a decrease of about 38.9% from $224.92 million in the previous period[52] - The ending cash and cash equivalents balance was approximately $530.38 million, compared to $470.60 million in the previous period, reflecting an increase of about 12.7%[52] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,199,028,028.60, reflecting a growth of 4.03% from CNY 5,959,020,827.97 at the end of the previous year[5] - Total current liabilities were CNY 1,248,308,071.79, compared to CNY 1,484,098,044.10 previously[30] - The total liabilities increased to ¥3,258,533,476.71 from ¥3,156,510,196.83, showing a growth of approximately 3.23%[45] - Long-term borrowings increased to CNY 999,238,137.82 from CNY 689,214,991.96[30] - The company's short-term borrowings decreased to CNY 484,841,770.00 from CNY 613,389,696.81[30] Equity and Shareholder Information - Shareholders' equity attributable to the parent company increased by 4.92% to CNY 2,940,494,551.89 from CNY 2,802,510,631.14 at the end of the previous year[5] - The total equity attributable to shareholders of the parent company increased to ¥2,940,494,551.89 from ¥2,802,510,631.14, representing a growth of about 4.93%[45] - The company has a total of 31,026,544 shares held by its largest shareholder, Zhu Xiaoping[24] Expenses and Income - The company's inventory increased by 50.53% to CNY 485,459,996.95, up from CNY 322,510,850.58, indicating an increase in production stock[23] - The company's financial expenses decreased by 51.06% to CNY 8,759,306.14 from CNY 17,898,376.80, due to the capitalization of interest expenses[23] - The company received government subsidies amounting to CNY 9,070,325.65, a decrease of 30.31% compared to CNY 13,015,588.30 in the previous year[23] - The company reported an increase in investment income by 1646.10% to CNY 2,463,766.47 from CNY 141,101.23 in the previous year[23] - Research and development expenses rose to ¥61,517,923.07 from ¥56,659,055.19, reflecting an increase of about 8.73%[32] - Tax expenses decreased to ¥1,076,155.70 from ¥6,010,278.61, a reduction of approximately 82.06%[34] - The company reported a financial asset impairment loss of ¥-1,694,678.65, compared to ¥-1,250,138.89 in the previous period[34] - Other income decreased to ¥9,070,325.65 from ¥13,015,588.30, indicating a decline of about 30.38%[32]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2022, representing a year-over-year increase of 15%[192]. - The net profit for the year was RMB 300 million, which is a 20% increase compared to the previous year[192]. - The company has set a revenue guidance of RMB 1.5 billion for the next fiscal year, indicating an expected growth of 25%[192]. - New product launches are expected to contribute an additional RMB 200 million in revenue in 2023[192]. - Cash flow from operating activities increased due to higher sales collections, indicating improved liquidity[69]. - The company's cash and cash equivalents at the end of 2022 were ¥777,248,693.86, representing 13.04% of total assets, up from 9.49% at the beginning of the year[71]. - The total sales revenue from major drug products accounted for over 10% of its main business income during the reporting period[31]. - The total sales amount of the top five customers is 596,766,787.57 yuan, accounting for 33.04% of the annual total sales[88]. Research and Development - The company is committed to continuous research and development, with plans to invest significantly in innovative drug formulations and technologies to maintain competitive advantage[20]. - The company has established two innovative drug research institutions focusing on BNCT and mRNA fields, with plans to enter the preclinical stage for early development projects by late 2023[28]. - The company has a strong R&D team of 550 people, which accounts for over one-third of its total workforce of 1,520 employees[40]. - Research and development expenses increased by 14.70% to approximately ¥263 million in 2022, reflecting the company's commitment to enhancing its R&D capabilities[54]. - The number of R&D personnel rose by 20.88% to 550 in 2022, with a notable increase in the number of master's degree holders by 37.58%[55]. - The company is actively pursuing collaborations with universities and research institutions to enhance its drug development capabilities[38]. - The company is developing a new high-efficiency pancreatic cancer treatment drug, currently in preclinical research, with pharmacology and GLP-level toxicity tests completed[55]. Product Development and Market Expansion - The company has developed new products, including a unique formulation of Diclofenac Sodium sustained-release capsules and a dry suspension for Trimebutine Maleate, which are expected to contribute to future revenue growth[24]. - The company is focused on expanding its market presence through strategic partnerships and collaborations, aiming to increase its share in both domestic and international markets[21]. - The company is actively expanding its product pipeline in the international innovative drug sector, focusing on boron drugs for cancer treatment, with ongoing collaborations with the Chinese Academy of Sciences and Zhejiang University[104]. - The company is enhancing its sales management by shifting from monthly to weekly management and optimizing its professional sales team to improve market penetration[107]. - The company is focusing on international market expansion, particularly in Europe and other countries, where its approved products have limited presence, indicating substantial growth potential[105]. - The company has signed significant sales and procurement contracts, with performance as of the reporting period being satisfactory[49]. Compliance and Governance - The company maintains a complete and independent governance structure, ensuring compliance with relevant laws and regulations, with no significant discrepancies in governance practices[118]. - The company has established an audit committee responsible for internal and external audit communication and supervision[162]. - The company has engaged in extensive communication with investors regarding its operational strategies and performance, ensuring no undisclosed major information leaks occurred[111]. - The remuneration structure for directors and senior management is based on performance evaluations conducted by the compensation committee[176]. - The company has appointed independent directors with extensive experience in law and finance, strengthening its governance structure[150]. Strategic Investments and Financial Management - The company plans to utilize the remaining unspent funds from its convertible bond issuance for project construction and liquidity support[77]. - The total investment amount during the reporting period is 740,379,635.66 yuan, representing an increase of 8.40% compared to the previous year's investment of 682,978,170.86 yuan[97]. - The company has made strategic investments in two subsidiaries, with a total investment of ¥15 million, acquiring 100% ownership in both[51]. - The company has a robust investor relations management system, ensuring timely and accurate information disclosure to all shareholders[116]. - The company reported a total investment of 137,781.37 million in committed projects, with 110,718.51 million actually invested by the end of the reporting period, achieving 80.4% of the planned investment[123]. Product Quality and Compliance - The company emphasizes adherence to GMP standards to ensure product quality and compliance with regulatory requirements[197]. - The company has received multiple certifications from international regulatory bodies, including the FDA and WHO, for various injectable products, indicating compliance with global quality standards[26]. - The company has received multiple GMP certifications for various products, including raw materials and dosage forms, from regulatory authorities in Hainan and Zhejiang provinces[33][34]. Future Outlook - The company anticipates a positive outlook for the next fiscal year, projecting a revenue growth rate of approximately 15% driven by new product launches and increased market demand[25]. - The company is considering strategic acquisitions to enhance its product portfolio and market presence[192]. - Multiple new products are expected to be approved in 2023 across the US, Netherlands, UK, Germany, and Canada, contributing to sustained sales growth, particularly from two newly approved contrast agents[105].

关于举行 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 | 证券代码：300630 | 证券简称：普利制药 | 公告编号：2023-040 | | --- | --- | --- | | 债券代码：123099 | 债券简称：普利转债 | | 海南普利制药股份有限公司 投 资 者 可 于 2023 年 5 月 10 日 （ 星 期 三 ） 15 ： 00 前访问 海南普利制药股份有限公司（以下简称"公司"）的《2022 年年度报告全文 及摘要》于 2023 年 4 月 25 日刊登在中国证监会创业板指定信息披露网站巨潮资 讯（http://www.cninfo.com.cn）。为了更好地与广大投资者进行交流，使投资 者能够进一步了解公司的经营状况、财务状况及未来发展规划等，公司拟举行 2022 年度业绩说明会。 一、活动时间 公司将于 2023 年 5 月 10 日（星期三）15:00-17:00 举行 2022 年度网上业 绩说明会。 二、活动方式 本次年度业绩说明会将采用网络远程的方式举行，投资者可在上述时间登陆 全景 ...

投资者关系活动记录表 证券代码：300630 证券简称：普利制药 海南普利制药股份有限公司投资者关系活动记录表 编号：2017-001 | --- | --- | --- | |----------------|-------------------------------|--------------------------------------| | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 上投摩根基金管理有限公司 叶敏 方钰涵 | | 人员姓名 | | 鹏华基金管理有限公司 段涛 桑翔宇 | | | 富国基金管理有限公司 姜恩铸 | | | | 长城基金管理有限公司 朱玮琳 | | | | 大成基金管理有限公司 邹建 | | | | 中海基金管理有限公司 郑磊 | | | | | 景顺长城基金管理有限公司 余捷涛 | | | 泰康资产管理有限责任公司 郑宁 | | ...

投资者关系活动记录表 证券代码：300630 证券简称：普利制药 海南普利制药股份有限公司投资者关系活动记录表 编号：2017-003 | --- | --- | --- | |----------------|-----------------------------------|-----------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 □分析师会议 | | | 类别 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | | 胡博新（国海证券股份有限公司 ）张羽 (九泰基金管理有 | | 人员姓名 | 限公司 ) | | | | | 周超泽（国海证券股份有限公司 ）何豪杰 (北京市星石投 | | | 资管理有限公司 ) | | | | 向秋静 (兴业证券股份有限公司 | ) 沈瑞 (财通证券股份有限 | | | 公司 ) | | | | 汤潇 ( 九泰基金管理有限 ...

投资者关系活动记录表 证券代码：300630 证券简称：普利制药 海南普利制药股份有限公司投资者关系活动记录表 编号：2018-001 | --- | --- | --- | |----------------|-------------------------|--------------------------------------------------------| | | | | | 投资者关系活动 | □ | 特定对象调研 □分析师会议 | | 类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | √ | 其他（深交所在公司举办"践行中国梦·走进上市公司" 投资 | | | 者开放日） | | | 参与单位名称及 | 1 | 、国元证券、华福证券、湘财证券、国泰君安证券、东方证 | | 人员姓名 | | 券、中信建投证券、上海证券等报名的投资者 | | | 2 视台等记者 | 、第一财经、全景网、中国证券报、证券日报、广东广播电 | | | 3 、深圳证券交易所领导 | | | | | | | 时间 | 2018 年 1 ...

投资者关系活动记录表 证券代码：300630 证券简称：普利制药 海南普利制药股份有限公司投资者关系活动记录表 编号：2018-002 | --- | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------------|-------| | | | | | | 投资者关系活动 | √ | 特定对象调研 □分析师会议 | | | 类别 | □ | 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | | | □ 现场参观 | | | | | □ | 其他 （请文字说明其他活动内容） | | | 参与单位名称及 | | 南方基金、上实投资、民森投资、富国基金、上海国际信托、 | | | 人员姓名 | 信达证券、工银瑞信等投资者； | | | | | | 海通证券、广发证券、中信银行、信达证券等金融机构； | | | | | 全景网、新财富、证券时报等媒体； | | | 时间 | 2018 年 5 月 15 | ...

Revenue and Profit - Revenue for Q3 2022 reached ¥575,087,948.20, an increase of 11.97% year-over-year, while year-to-date revenue totaled ¥1,370,691,220.82, up 20.59% compared to the same period last year[7]. - Net profit attributable to shareholders for Q3 2022 was ¥167,852,734.59, reflecting a 1.70% increase year-over-year, with a year-to-date net profit of ¥455,464,130.48, up 16.73%[7]. - Basic earnings per share for Q3 2022 were ¥0.38, up 2.70% year-over-year, while diluted earnings per share also stood at ¥0.38[7]. - Total operating revenue for the current period reached ¥1,370,691,220.82, an increase of 20.6% compared to ¥1,136,643,420.66 in the previous period[28]. - Net profit for the current period was ¥455,464,130.48, representing a 16.7% increase from ¥390,176,301.10 in the previous period[30]. - Basic and diluted earnings per share were both ¥1.04, compared to ¥0.89 in the previous period[33]. Cash Flow and Liquidity - The company's cash flow from operating activities showed a significant decline, with a year-to-date net cash flow of ¥82,185,693.73, down 47.55% compared to the previous year[7]. - Cash flow from operating activities totaled ¥1,274,245,066.13, a decrease from ¥1,417,676,860.54 in the previous period[34]. - The net cash flow from operating activities was 82,185,693.73, a decrease of 47.5% compared to 156,679,118.33 from the previous period[37]. - The total cash and cash equivalents at the end of the period were 144,734,657.17, down from 623,880,152.83, reflecting a significant decrease[37]. - The company's cash and cash equivalents decreased to CNY 184.01 million from CNY 442.26 million, representing a decline of approximately 58.4%[21]. Assets and Liabilities - Total assets increased to ¥5,605,973,210.82, representing a growth of 20.24% from the end of the previous year[7]. - The total assets amounted to ¥5,605,973,210.82, compared to ¥4,662,239,616.98 in the previous period[27]. - The company's equity attributable to shareholders rose to ¥2,867,008,388.53, marking a 12.80% increase from the end of the previous year[7]. - The total liabilities reached ¥2,738,964,822.29, an increase from ¥2,120,484,168.47 in the previous period[27]. - The company’s total liabilities increased to CNY 1.16 billion, compared to CNY 1.04 billion, representing a rise of about 11.3%[24]. Accounts Receivable and Inventory - Accounts receivable increased by 42.20% to ¥1,245,343,655.06, attributed to the expansion of business scale[12]. - Accounts receivable increased significantly to CNY 1.25 billion, up from CNY 875.76 million, indicating a growth of around 42.2%[21]. - Inventory levels rose by 46.57% to ¥384,257,012.35, indicating an increase in raw material stockpiling[12]. - Inventory rose to CNY 384.26 million, compared to CNY 262.17 million, marking an increase of approximately 46.5%[24]. Borrowings and Financing - Long-term borrowings surged by 248.78% to ¥639,557,744.96, reflecting increased financing activities[12]. - The company's short-term borrowings increased to CNY 538.29 million from CNY 347.11 million, reflecting a rise of about 55.0%[24]. - The net cash flow from financing activities was 477,193,943.52, a decrease of 47.4% from 905,996,049.53 in the previous period[37]. Government Subsidies and Expenses - The company reported government subsidies of ¥21,147,279.58 year-to-date, an increase of 185.19% compared to the previous year[12]. - Research and development expenses amounted to ¥258,238,348.53, up from ¥204,105,266.69 in the previous period[30]. - Financial expenses increased significantly to ¥63,728,301.67, compared to ¥27,098,855.39 in the previous period[30]. - The cash paid for various taxes was 198,727,567.27, up from 116,900,148.43, representing an increase of 69.9%[37]. - The cash paid to employees and for employee benefits was 121,984,431.11, compared to 77,817,173.17, marking an increase of 56.6%[37].

Financial Performance - The company's operating revenue for the reporting period reached ¥795,603,272.62, representing a year-on-year increase of 27.69% compared to ¥623,056,090.07[26]. - The net profit attributable to shareholders was ¥287,611,395.89, up 27.75% from ¥225,135,214.40 in the same period last year[26]. - The basic earnings per share increased to ¥0.66, reflecting a growth of 26.92% compared to ¥0.52 from the previous year[26]. - Total assets at the end of the reporting period amounted to ¥5,406,277,436.29, marking a 15.96% increase from ¥4,662,239,616.98 at the end of the previous year[26]. - The weighted average return on equity for the reporting period was 10.71%, slightly up from 10.53% in the previous year[26]. - The gross margin improved to 45%, up from 40% in the previous year, due to cost optimization measures[68]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion CNY for the first half of 2022, representing a 20% year-over-year growth[68]. - The company has provided guidance for the second half of 2022, projecting a revenue growth of 10% to 12% compared to the first half[80]. Research and Development - The company is involved in the development of new products and technologies to improve its competitive edge[1]. - The company has a total of over 140 ongoing research projects, focusing on first generics, modified new drugs, and new chemical entities[42]. - The R&D team consists of 482 personnel, accounting for over one-third of the total workforce of 1,386 employees[53]. - The company is focusing on high-difficulty generic drugs and innovative drugs, with significant R&D investments aimed at developing high-value products[46]. - The company has established a standardized management system for the entire R&D process, ensuring smooth progress towards R&D goals[88]. - The company has a comprehensive R&D process that includes project responsibility systems and competitive evaluation methods, ensuring high standards in product development and registration[117]. - The company is focusing on research and development of new drugs, with a significant number of projects aimed at addressing unmet medical needs in various markets[100]. Market Expansion - The company is focused on expanding its market presence and enhancing its product offerings[1]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[70]. - The company is actively pursuing market expansion strategies in both domestic and international markets to enhance its competitive edge[104]. - The company is expanding its market presence in Europe, with plans to enter three new countries by Q4 2022, aiming for a 5% market share in these regions[82]. - The company has established close communication channels with drug regulatory agencies in nearly 20 countries, with over 10 products approved by the FDA within 10 months of submission[60]. Quality Management - The company has established a comprehensive quality management system and has passed various international quality audits, including those from the FDA and EMA[38]. - The company emphasizes quality control throughout the drug development and production process, which is critical for maintaining its market position[110]. - Each batch of products undergoes strict quality inspection before being released for sale, ensuring compliance with quality standards[96]. - The company has obtained several GMP/cGMP certifications for its raw materials and finished products, ensuring high-quality standards in production[110]. Corporate Governance - The company has a commitment to ensuring the accuracy and completeness of its financial reports, with all board members present for the review[6]. - The company has maintained its information disclosure practices without changes during the reporting period[22]. - The company emphasizes the importance of risk management and has outlined potential risks and corresponding countermeasures in its report[6]. - The company is committed to complying with the disclosure requirements set forth by the Shenzhen Stock Exchange regarding pharmaceutical and biological products[97]. Social Responsibility - The company actively engages in social responsibility initiatives, promoting health and wellness among employees through various cultural activities[188]. - The company donated a total of 133,000 pieces of essential medical supplies during the COVID-19 pandemic, including protective clothing and N95 masks, to support epidemic prevention efforts in Hainan Province[195]. - The company was awarded the "Special Contribution Award" by the China Red Cross for its efforts in combating the COVID-19 pandemic[195]. - The company emphasizes employee rights protection and has implemented a competitive salary structure and stock incentive plans to enhance employee retention and motivation[189]. Environmental Responsibility - The company has established a wastewater treatment system to ensure that all wastewater meets discharge standards before being released[182]. - The company strictly adheres to environmental protection standards and regulations, including the Environmental Protection Law of the People's Republic of China and the Pharmaceutical Industry Water Pollution Discharge Standards[187]. - The company has implemented measures to reduce carbon emissions, including the use of low-noise energy-saving equipment and noise control measures, ensuring compliance with noise emission standards[187]. - The company has implemented a waste management system for hazardous and non-hazardous waste, ensuring proper disposal through qualified third-party services[186]. Investment and Financing - The total investment during the reporting period amounted to RMB 655,505,437.10, representing a 36.36% increase compared to RMB 480,720,106.21 in the same period last year[136]. - The company has invested RMB 43,958,834.36 in the construction of a production line capable of producing 1.5 billion dosage forms, with a cumulative actual investment of RMB 475,193,000.00[137]. - The company has a maximum debt limit of RMB 46,020,000.00 secured by a mortgage on fixed assets, with a loan balance of RMB 45,000,000.00 as of June 30, 2022[133]. - The cumulative realized income from investments as of the reporting period is RMB 634,274,166.93[140].